Dr. Kernen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
130 Town Center Drive
Suite 101
Troy, MI 48084Phone+1 248-740-0670
Education & Training
Corewell Health East Beaumont (Royal Oak)Residency, Urology, 1995 - 1999- Corewell Health East Beaumont (Royal Oak)Residency, Surgery, 1993 - 1995
Wayne State University School of MedicineClass of 1993
Certifications & Licensure
MI State Medical License 2000 - 2025- American Board of Urology Urology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Top MD Consumers Checkbook
Clinical Trials
- Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer Start of enrollment: 2012 Jan 01
- TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer Start of enrollment: 2021 May 05
Publications & Presentations
PubMed
- 24 citationsUrine kidney injury molecule-1: a potential non-invasive biomarker for patients with renal cell carcinomaPing L. Zhang, Joseph W. Mashni, Venkata S. Sabbisetti, Charles M. Schworer, George S. Wilson
International Urology and Nephrology. 2014-02-01 - 125 citationsDose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost ...Alvaro Martinez, Jose Gonzalez, Hong Ye, Mihai Ghilezan, Sugandh Shetty
International Journal of Radiation Oncology, Biology, Physics. 2011-02-01 - 14 citationsNational Cancer Database Comparison of Radical Cystectomy vs Chemoradiotherapy for Muscle‐Invasive Bladder Cancer: Implications of Using Clinical vs Pathologic StagingHong-Yiou Lin, Hong Ye, Kenneth M Kernen, Jason Hafron, Daniel J. Krauss
Cancer Medicine. 2018-10-10
Press Mentions
Tavanta Therapeutics Announces Completion of Enrollment in Pivotal Phase 3 Trial of TAVT-45 for the Treatment of Metastatic Prostate CancerAugust 1st, 2022- Temporary Implant Provides Relief for Men with Enlarged ProstateOctober 19th, 2021
- iTind System for BPH Treatment Reaches Two Major Milestones: First Commercial Treatments and CMS Reimbursement Code AssignedNovember 17th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
